Westergaard, David https://orcid.org/0000-0003-0128-8432
Jørgensen, Frederik Hytting
Waaben, Jens
Jung, Alexander Wolfgang
Lademann, Mette
Hansen, Thomas Folkmann https://orcid.org/0000-0001-6703-7762
Cremers, Jolien
Ostrowski, Sisse Rye https://orcid.org/0000-0001-5288-3851
Pedersen, Ole Birger Vesterager https://orcid.org/0000-0003-2312-5976
,
Reguant, Roc https://orcid.org/0000-0002-0350-3899
Jørgensen, Isabella Friis https://orcid.org/0000-0001-5694-4332
Fitzgerald, Tom https://orcid.org/0000-0002-2370-8496
Birney, Ewan https://orcid.org/0000-0001-8314-8497
Banasik, Karina https://orcid.org/0000-0003-2489-2499
Mortensen, Laust https://orcid.org/0000-0002-6399-495X
Brunak, Søren https://orcid.org/0000-0003-0316-5866
Funding for this research was provided by:
Novo Nordisk Foundation
Article History
Received: 21 August 2023
Accepted: 16 August 2024
First Online: 28 August 2024
Competing interests
: Søren Brunak has ownerships in Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S, Eli Lilly & Co and managing board memberships in Proscion A/S. All other authors declare no competing interests.